VanEck Semiconductor ETF vs Zimmer Biomet Holdings Inc — how do they compare? VanEck Semiconductor ETF trades at $584.05, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while VanEck Semiconductor ETF pays none, and VanEck Semiconductor ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| SMH | ZBH | |
|---|---|---|
52-Week High | $668.91 | $107.71 |
52-Week Low | $283.95 | $79.58 |
Market Cap | — | $17.36B |
Sector | — | Health |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
SMH trades at $584.08, up 5.08% in the last 24 hours, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The semiconductor ETF faces mixed sentiment as AI-driven chip stocks correct despite strong Q2 earnings. Recent institutional buying by firms like Empirical Wealth Management and Assetmark Inc. contrasts with broader market concerns about semiconductor sector rotation and China's potential export controls on AI technologies.
Near-term outlook remains cautious due to technical bearish signals and sector volatility, though oversold RSI levels suggest potential for a rebound. Key risks include geopolitical tensions, AI capex slowdown fears, and concentrated portfolio exposure. The ETF's performance hinges on semiconductor earnings momentum and hyperscaler spending trends through 2027.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →